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Introduction: Periostin (Postn) is a secreted cell adhesion protein that activates signaling pathways to promote
cancer cell survival, angiogenesis, invasion, and metastasis. Interestingly, Postn is frequently overexpressed in
numerous human cancers, including breast, lung, colon, pancreatic, and ovarian cancer.
Methods: Using transgenic mice expressing the Neu oncogene in the mammary epithelium crossed into
Postn-deficient animals, we have assessed the effect of Postn gene deletion on Neu-driven mammary tumorigenesis.
Results: Although Postn is exclusively expressed in the stromal fibroblasts of the mammary gland, Postn deletion does
not affect mammary gland outgrowth during development or pregnancy. Furthermore, we find that loss of Postn in
the mammary epithelium does not alter breast tumor initiation or growth in mouse mammary tumor virus (MMTV)-Neu
expressing mice but results in an apocrine-like tumor phenotype. Surprisingly, we find that tumors derived from
Postn-null animals express low levels of Notch protein and Hey1 mRNA but increased expression of androgen
receptor (AR) and AR target genes. We show that tumor cells derived from wild-type animals do not proliferate when
transplanted in a Postn-null environment but that this growth defect is rescued by the overexpression of active Notch or
the AR target gene prolactin-induced protein (PIP/GCDFP-15).
Conclusions: Together our data suggest that loss of Postn in an ErbB2/Neu/HER2 overexpression model results in
apocrine-like tumors that activate an AR-dependent pathway. This may have important implications for the treatment of
breast cancers involving the therapeutic targeting of periostin or Notch signaling.Introduction
The epidermal growth factor receptor (EGFR), or HER/
ErbB family of receptor tyrosine kinases (RTKs), includes
four members, EGFR/HER1/ErbB1, HER2/ErbB2/Neu,
HER3/ErbB3, and HER4/ErbB4 playing a role in multiple
biological processes such as proliferation, differentiation,
migration, and apoptosis [1-3]. Activation of the intra-
cellular kinase domain, through the phosphorylation of
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whose binding initiates downstream signaling events [4].
HER2 (ErbB-2/Neu) is overexpressed in approximately
30% of primary human breast cancers (reviewed [5,6]).
HER2 overexpression leads to an aggressive tumor
phenotype as high levels of HER2 expression are ob-
served in many invasive human ductal carcinomas, but
rarely observed in benign breast disorders. Patients with
cancer whose tumors overexpress HER2 receptors tend
to have a more metastatic disease with a poor prognosis
[5,7].
Transgenic studies have provided direct evidence
supporting a role for HER2 in mammary tumorigenesis.
Mice expressing a mouse mammary tumor virusThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HER2, rapidly develop mammary tumors that histologi-
cally resemble human breast carcinomas overexpressing
HER2 [8-11].
Periostin (Postn), also designated osteoblast-specific
factor-2 (OSF-2), is a disulfide-linked, secreted cell adhe-
sion protein that was originally isolated as an osteoblast-
and mesenchyme-specific factor believed to be involved
in osteoblast recruitment, attachment, and spreading
[12,13]. Postn is primarily expressed in collagen-rich
fibrous connective tissues that are subjected to constant
mechanical stresses, such as in the periosteum and peri-
odontal ligaments, where it functions in the formation
and structural maintenance of bones and teeth [12,13].
Although approximately 14% of Postn-null mice die
postnatally before weaning [14], the remaining Postn-
deficient mice exhibit severe growth retardation, incisor
enamel defects, and an early-onset periodontal disease-
like phenotype [14].
Postn binds directly to many extracellular matrix
(ECM) proteins such as collagen, fibronectin, tenascin-
C, and Postn itself [15]. It also acts as a ligand for sev-
eral integrins such as αvβ3, α6β4 and αvβ5 to mediate
cell adhesion, migration and survival [12,15,16]. Inter-
estingly, Postn has also been linked to invasion, cellu-
lar survival, angiogenesis, and metastasis in epithelial
tumors, suggesting a role for Postn in tumor progres-
sion [13,15,17,18]. Recent clinical evidence has also
revealed that Postn is overexpressed in breast cancers
[19] and involved in the progression of mammary tu-
mors to invasive and metastatic cancers. More import-
antly, acquired expression of Postn by breast cancers is
associated with increased angiogenesis and metastasis
[20,21]. Recently, Postn has been found to be critical
for the establishment of tumor cell niche and the
reactivation of dormant tumor cells [22,23]. Interest-
ingly, Postn appears to play a role in regulating
the availability of Wnt factors to tumor-initiating
cells [22].
The androgen receptor (AR) plays an important role
in hormone-dependent cancers [24]. In most cases, AR
usually triggers its action by binding to testosterone and
activating gene expression following nuclear transloca-
tion. Interestingly, the AR has recently received much
attention as a novel therapeutic target in breast cancer
[24-26]. AR expression and phosphorylation has been
observed in a number of breast cancers [25,27]. How-
ever, confusing results have emerged from the analyses
of the various breast cancer subtypes. Surprisingly, high
levels of AR activity have been associated with better
outcomes in estrogen receptor (ER)-positive cancers but
with poor prognosis in ER-negative and HER2+ cancers
[26,28-30]. These findings suggest a role for AR activa-
tion in a proportion of HER2+ cancers.In polyoma middle T (PyMT)-induced mammary tu-
mors, Postn was found to be dispensable for primary
tumor initiation and growth [22] but required for lung
metastasis. As the various murine models of breast
cancer display differences in latency and progression, we
tested the role of Postn in MMTV-Neu (NDL2-5) mice
[31], expressing an activated Neu/ErbB2/HER2 from the
MMTV promoter. As for MMTV-PyMT mice, our re-
sults show that Postn deletion does not affect mammary
gland development or tumor initiation in MMTV-Neu
mice. However, tumors from Postn-null mice exhibit
apocrine-like features and express low levels of active
Notch1 but high levels of AR and prolactin-induced pro-
tein (PIP). Mammary tumor cells derived from wild-type
MMTV-PyMT mice (Met1) failed to grow in Postn-null
mice when injected subcutaneously. However, re-
expression of active Notch1 or PIP in Met1 tumor cells
rescued the growth deficit in a Postn-null environment,
suggesting that the loss of Postn selects for an
AR-dependent pathway. Overall our results show that
Postn deletion results in decreased Notch1 levels and a
switch to a molecular apocrine subtype in a Her2-
positive context.
Materials and methods
Animal analysis and genotyping
MMTV-NeuNDL were as described previously [32].
Postn(−/−) mice in a C57Bl/6 background were back-
crossed into FVB/N mice. The FVB/N contribution was
evaluated after two generations using Marker-assisted
Accelerated Backcrossing (MAX-BAX™; Charles River
Laboratories, Wilmington, MA, USA). Heterozygote
Postn(+/−) mice from the 3rd backcross (95% FVB/N)
were used for subsequent breeding to MMTV-NeuNDL
males to obtained the desired genotypes. All animals
were genotyped by polymerase chain reaction (PCR)
analysis. Mouse DNA was extracted from mouse ear
clippings and purified using the DNeasy™ blood and tis-
sue kit according to the manufacturer’s protocol (Qiagen,
Venlo, Netherlands). For Postn genotyping, three primers
were used. Primer 1: 5′ – AGTGTGCAGATGT
TTGCTTG – 3′, primer 2: 5′ – ACGAAATACAGTTT
GGTAATCC – 3′, and primer 3: 5′ – CAGCGCATCGC
CTTCTATCG – 3′. Genotyping of MMTV-NeuNDL
mice was performed using the following primer pair: 5′ –
GTTTCCTGCAGCAGCCTACGC – 3′ and 5′ – TT
CCGGAACCCACATCAGGCC – 3′.
For weight determination, Postn+/+, Postn+/−, and
Postn−/− mice were weighed with a scale twice a week
for 9 weeks to establish a growth curve. Weights were
averaged to establish the data points. NeuNDL Postn+/+,
NeuNDL Postn+/−, and NeuNDL Postn−/− mice were
palpated once a week, every week starting at 4 months
of age. A total tumor burden of 1.7 cm3 was considered
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lines. Animal studies were approved by the University of
Ottawa animal ethics board (NSI-73). Care and use of
experimental mice followed the guidelines established by
the Canadian Council on Animal Care.
Expression vector and tissue culture
The MMTV-PyMT-derived Met-1 cells [33] were pro-
vided by A. Borowsky and maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/10% fetal calf serum
(FCS) at 37°C in 5% CO2. The murine Postn cDNA was
a kind gift from A. Kudo, (Tokyo; [13]). The Notch-
ΔNLS expression vector was provided by P. Jolicoeur
(Montreal, IRCM) and the NICD cDNA was obtained
from Addgene (Cambridge, MA, USA). Dominant-
negative MAML1 was kindly provided by J. Aster
(Boston, Harvard). The PIP cDNA was PCR amplified
(5′-CCCTCGAGATGCAGGGTCTCTCATTCAC- 3′
and 5′- CCGAATTCTTAATTCATTCGCACAG TATT
A - 3′) and all expression vectors were generated in the
pLPCX retroviral backbone. Retrovirus using individual
vectors was generated using the Plat-E retroviral pack-
aging cell line and used to transduce Met1 cells as de-
scribed previously [34,35] and puromycin-resistant
pools (1ug/ml; Calbiochem, San Diego, CA, USA) were
expanded and assessed for expression by Western blot
(Postn and NICD) or Q-PCR (dnMAML1, ΔNLS and
PIP). For heterotopic transplants, 106 cells were injected
subcutaneously into the flanks of 10- to 12-week-old
FVB/N female mice (n = 5). Tumor volumes were moni-
tored weekly for 28 days using calipers.
Western blot analysis and antibodies
Mammary tumors or mammary glands were crushed in
liquid nitrogen with a mortar and pestle and then trans-
ferred to an Eppendorf tube and lysed in RIPA buffer
(50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.0% Triton-
X, 1.0% Nonidet P-40, 0.5% sodium dideoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 2 mM EDTA), containing
10 mM NaF, 1 mM DTT, 10 μg/ml leupeptin, 10 μg/ml
aprotinin, 0.1 mM benzamidine, 10 mM β-glycerol phos-
phate, 1 mM PMSF, 0.25 mM Na3VO4, and 10 μg/ml
pepstatin. Protein concentrations were measured using
the Bio-Rad protein assay dye reagent (Bio-Rad
Laboratories, Hercules, CA, USA). Samples containing
40 μg of total protein were resolved by SDS-PAGE and
transferred to polyvinylidene fluoride (PVDF) membrane
(PerkinElmer, Waltham, MA, USA). Membranes were then
probed with various antibodies as previously described
[36]. The primary antibodies were detected using conju-
gated horseradish peroxidase (HRP)-labeled secondary
antibodies and detected using Western Lightning™ Plus-
ECL enhanced chemiluminescence (PerkinElmer). Reactive
bands were visualized by exposure to X-ray film. Proteinexpression levels were quantified using densitometric
analysis using ImageJ and normalized to tubulin expres-
sion. Statistical analysis was performed using a two-tailed
unpaired Student’s t test.
The following antibodies were purchased and used ac-
cording to the manufacturer’s protocols: Postn (R&D
Systems, Minneapolis, MN, USA), pAkt-S473, Akt,
NICD, Notch1 (Cell Signaling, Danvers, MA, USA),
cyclin D1, (Santa Cruz Technology, Dallas, TX, USA),
pY397FAK, focal adhesion kinase (FAK) (BD Biosciences,
San Jose, CA, USA), androgen receptor, CD31 (Abcam,
Cambridge, UK), ErbB2 (Calbiochem, clone ab-3), Ki67,
non-phospho beta catenin (EMD Millipore, Billerica,
MA, USA), tubulin (Sigma-Aldrich, St Louis, MO,
USA), γ-secretase inhibitor, (In solution inhibitor
X; Calbiochem).
Immunohistochemical analysis and mammary whole
mount
For mammary gland whole mounts, the 4th inguinal
mammary gland was excised processed for hematoxylin
staining as described [37]. For immunohistochemistry,
the mammary glands and mammary tumors were ex-
cised and fixed in 10% formalin buffer overnight at room
temperature. The samples were then paraffin-embedded
and sectioned onto microscope slides. The mammary
gland and mammary tumor sections were deparafinized
and heat-mediated antigen retrieval was performed using
10 mM citrate buffer followed by incubation with a pri-
mary antibody in 1.5% normal goat serum at 4°C over-
night in a humidified chamber. The sections were then
washed and incubated with biotin- or HRP-conjugated
secondary antibody diluted in 1.5% normal goat-blocking
serum at room temperature for 30 minutes. Color devel-
opment was achieved using DAB followed by hematoxylin
counterstain. Human tissue microarrays (TMA; BR962)
were purchased from US Biomax, Inc (Rockville, MD,
USA) and stained for Postn.
Microarray, quantitative PCR analysis and luciferase
assays
RNA was prepared according to the manufacturer’s
protocol by directly lysing frozen tumors and cultured
monolayers into Trizol (Invitrogen, Carlsbad, CA, USA).
The RNA was then treated with DNaseI (Qiagen) to re-
move any contaminating genomic DNA. For Affymetrix
microarrays, 5 μg of total RNA from two independent
tumors for both wild-type and Postn(−/−) were sub-
jected to hybridization to the Mouse Gene 1.0 ST array
v.1 (Affymetrix, Santa Clara, CA, USA). The raw output
data analysis was performed using the online tool
WEBARRAY - Online Microarray Data Analysis - in
‘Linear model statistical analysis’ mode. The data was
normalized using the RMA algorithm. For cDNA
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RT-PCR reaction using SuperscriptIII reverse transcript-
ase (Invitrogen) following the manufacturer’s protocol.
The resulting cDNA was used in quantitative real-time
polymerase chain reaction (qRT-PCR) using SYBR Green
chemistry (Bio-Rad). Q-PCR was performed in a 96-well
format using an Applied Biosystems 7500 real-time PCR
system (Applied Biosystems, Waltham, MD, USA). The
primers used are listed in Table S1 in Additional file 1.
Wnt activity measurements in Met1 pools stably
expressing Postn or NICD cDNAs were performed by
cotransfection with the Top flash/Renilla or Fop flash/
Renilla plasmid system and luciferase assays were per-
formed using the Dual-Glo™ Luciferase Assay System
(Promega, Madison, WI, USA) according to the manu-
facturer’s instructions.
Statistical analysis
Animal survival was subjected to Kaplan-Meier analysis
and significance was evaluated using the log rank test.
For tumor volume measurements, the average tumor
volume from five mice was plotted over time and ana-
lyzed using a two-tailed unpaired Student’s t test. Q-
PCR gene expression data were normalized to GAPDH
levels and calculated using the comparative Ct (ddCt)
method and the significance in the difference of the
means between the groups was calculated using a two-
tailed unpaired Student’s t test. The proportion of nu-
clear AR was calculated from at least 1,000 nuclei from
three independent tumors, compared using Student’s t
test and shown as the average and standard error of the
mean (S.E.M). Results were considered statistically sig-
nificant at P <0.05.
Results
Postn is not required for mammary gland development
Previous reports have shown that Postn-null mice are vi-
able but display impaired periodontal ligament develop-
ment [14,38,39]. Therefore, prior to the introduction of
the Postn-null allele into MMTV-NeuNDL mice, we
assessed Postn expression and whether Postn ablation
was compatible with normal mammary gland develop-
ment. Mice carrying a LacZ knock-in [14] into the Postn
locus were bred into an FVB/N background and assessed
for Postn expression and mammary gland development
in virgin and pregnant females. Postn protein isoforms
[40] are readily detectable in the mammary glands of
8-week-old virgin wild-type females but absent from
Postn-null glands (Figure S1 in Additional file 2).
Mammary gland whole mount analyses (Figure S1 in
Additional file 2) revealed normal branching and ductal
outgrowth in Postn(−/−) nulliparous females, indistin-
guishable from that of control mice. Similarly, 12-week-
old pregnant (14.5dpc) Postn-deficient females displayedextensive outgrowth and arborization that was similar
to wild-type or Postn(+/−) littermates (Figure S1 in
Additional file 2). Histological analysis by hematoxylin
and eosin (H&E) staining of nulliparous mammary gland
showed no defects in the ductal epithelial and stromal
layers (Figure S1L-O in Additional file 2). Supporting
this, we observed that FVB/N Postn−/− female mice were
able to lactate and produce viable litters through mul-
tiple rounds of pregnancy (data not shown). However, in
contrast to what has been observed in a C57/Bl6 back-
ground [14], the viable Postn-null pups displayed a mild
growth retardation phenotype that became negligible by
9 weeks of age (data not shown). Together, these results
suggest that Postn is not required for normal mammary
gland development.
Postn has been shown to be expressed in the stromal
and epithelial compartment of the embryonic heart
[41]. Similarly, Postn expression was detected in both
the stroma and tumor cells of human breast cancer
samples [19-21]. Therefore, the cell type-specific ex-
pression of Postn in the mouse mammary gland was
investigated using immunohistochemical analysis of
paraffin-embedded sections. Examination of mammary
tissue derived from Postn+/+ and Postn+/− mice revealed
that Postn is expressed in the stromal cells lining the
ducts and lobules, but not in the mammary epithelial
cells (Figure S1 in Additional file 2). Postn reactivity
was also observed in the intercellular space between the
adipocytes.
Loss of Postn does not affect survival in NeuNDL mice
Postn has been shown to play multiple roles in tumor
progression through activation of pathways involved in
invasion, cellular survival, angiogenesis, and metastasis
[15,42]. Furthermore, Postn expression levels were found
to be increased in a high proportion of breast cancers
[19-21]. Supporting this, our analysis of human tissue
microarray (Figure 1) revealed that about 46% (16/35) of
human breast cancers acquire Postn expression irre-
spective of receptor status (Table 1).
Therefore, to investigate whether Postn expression is
required for mammary tumorigenesis in an ErbB2-
positive model, the in-frame Neu deletion transgene
under the MMTV promoter (MMTV-NeuNDL2-5) [31]
was introduced into mice lacking Postn. Postn wild-type,
heterozygotes and null NeuNDL virgin females were
monitored for tumor development. In all Postn geno-
types, hyperplastic lesions or palpable tumors could be
detected as early as 16 weeks of age with no differences
in the number of observed lesions (Figure 2A,B and
Figure S2 in Additional file 3). Similarly, no differences
were observed in tumor growth as all the Postn geno-
types reached end point with similar kinetics (Figure 2G).
Further analysis of NeuNDL-Postn+/+ and Postn−/−
Figure 1 Postn expression in human breast cancers. Anti-Postn
immunohistochemistry showing Postn expression in the stroma of
human mammary glands bearing hyperplastic lesions (A). However,
some mammary tumors were found to acquire Postn expression
independently of receptor status. Representatives of Postn-negative
(A-B) and positive (C-D) are shown. The expression data are
summarized in Table 1.
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intraductal papillary carcinomas (Figure 2C-F) that
retained Neu expression (Figure 2H,J). In addition, no
changes were observed in CD31-positive tumor blood
vessels or in the Ki-67 proliferative index (Figure S3 in
Additional file 4). These findings suggest that Postn ab-
lation does not prevent or delay primary tumor initiation
or growth. Similar findings have been reported in the
MMTV-PyMT mouse model [22].
In human breast tumor tissues, Postn was reported to
be highly expressed in the stromal cells immediately sur-
rounding the tumor and in late-stage mammary tumors
[19,21]. Supporting this, immunohistochemical analysis of
Postn in NeuNDL Postn+/+ and Postn+/− tumors shows
expression in the stromal compartment around theTable 1 Biomax US BR962 breast cancer TMA was
stained with an anti-Postn antibody (see Figure 1) and
the results were scored as a percentage of the total cores
on the TMA
BR962 Postn + ve* AR + ve
35 Tumors 16/35 (46%) 3/16 (9%)#
13 Non-malignant 0/13 (0%) 10/13 (77%)§
*Indicates the percentage of cores that displayed Postn expression by the
cancer epithelia (see Figure 1G). #The AR expression scores of the three cores
were reported to range between 5 and 30% positivity by the manufacturer.
§All but three cores were reported to range between 1 and 50% positivity by
the manufacturer. Expression levels were reported as variable. TMA, tissue
microarray; Postn, periostin; AR, androgen receptor.epithelial mammary tumors. Interestingly, Postn was
undetectable in the mammary tumor cells (Figure 2K).
Similarly, Western blot analysis of mammary glands
and tumors shows higher levels of Postn in whole mam-
mary gland containing a higher proportion of mammary
fibroblasts (Figure 2L). Together, these results suggest that
Postn expression is restricted to the stromal compartment
of NDL tumors and is not upregulated in the tumor epi-
thelium in MMTV-Neu-NDL mice.
To further investigate the effect of Postn deletion in
mammary tumorigenesis, we surveyed a number of
markers activated downstream of Postn treatment. Postn
stimulation has been previously shown to activate FAK
and Akt through β3 or β4 integrin binding [16,43,44].
Western blot analysis showed an overall 2-fold decrease
in the levels of phospho-FAK-Y397 protein kinase
(Figure 3A). However, β3 integrin levels remained un-
changed in Postn-null tumors (not shown). Interestingly,
the levels of phospho-Akt-S473 were not affected,
suggesting that the loss of Postn can preferentially affect
specific pathways in mammary tumors. Similarly, ErbB3
levels were unaffected (not shown). Supporting our
Ki-67 observations, cyclin D1 levels also remained un-
changed in tumors derived from Postn-null animals
(Figure 3B).
Loss of Postn results in reduced Notch1 activity
Although Postn has been shown to be overexpressed in
a high proportion of human tumors and to play a role in
tumor cell growth in vitro [15,19-21,42], Postn deletion
has no effect on tumor development in ErbB2- (Figure 2)
or PyMT-expressing mice [22]. However, previous data
have shown that Postn plays a critical role in the estab-
lishment of tumor cell niche at secondary sites [22].
Supporting this, administration of Postn neutralizing
antibodies in xenograft models of breast and ovarian
cancers also suppressed invasion and metastasis [45,46].
Therefore, in light of these observations we tested
whether mammary tumor cells injected at heterotopic
sites could form tumors in a Postn-null environment. As
skin tissue is a Postn-rich environment [47,48] we tested
the requirement for Postn in tumor growth using sub-
cutaneous injections. As PyMT also activates ErbB2
downstream signaling during tumorigenesis [49], we
used MMTV-PyMT-derived Met-1 cells [33] in an isograft
model.
Whereas large tumors were observed in Postn wild-
type females, little or no growth was observed following
the subcutaneous injection of Met-1 cells into Postn-
deficient animals. Tumor volume measurements showed
that Met-1 cells in a wild-type environment grew to
about 10 times the size of the tumors collected following
injections into Postn-null mice (Figure 3C,D). In the
Postn-null background, no significant increase in tumor
Figure 2 Loss of Postn does not affect tumor growth in MMTV-Neu mice. (A and B) Representative mammary gland whole mounts from 4
month old virgin females showing multiple tumor foci in both wildtype and Postn(-/-) mice. (C-F) H & E staining of representative tumors
collected at end point from wildtype (C and E) and Postn-null (D and F) mice. Both cystic (C and D) and solid tumors (E and F) were observed.
(G) Kaplan-Meier survival analysis of tumor-bearing mice. Log rank testing showed no significant delay in tumor progression for Postn(-/-) mice
when compared to heterozygotes or wildtype mice. All three genotypes reached end point with similar kinetics. (H-K) Paraffin-embedded
sections were stained for ErbB2 (H and J) or Postn (I and K). Tumors arising in Postn-null females retained Neu expression. In Neu-induced
tumors, Postn expression was restricted to the stromal compartment and was never found in the tumor cells. (L) Western blot analysis of
mammary tumors (T) and whole gland (G) lysates. Supporting the IHC data, Postn was found to be expressed at low levels in tumors containing
a small amount of stromal fibroblasts.
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mice had to be euthanized beyond 5 weeks due to very
large tumors (data not shown). Interestingly, exogenous
expression of Postn in Met-1 cells did not rescue their
growth defect in a Postn-null environment. As those an-
imals never expressed Postn protein, this is likely due to
immune rejection of Postn-expressing cells in null mice.
These data strongly suggest that Postn is required for
sustaining tumor growth at heterotopic sites.
Postn has been shown to interact with Wnt and to
potentiate Wnt signaling to enhance tumor cell seeding
[22]. Interestingly, Western blot analysis for β-catenin
(or active β-catenin; not shown) levels, nuclear loca-
lization or activity showed no difference in tumors
derived from Postn-null mice (Figure S4 in Additional
file 5), suggesting that the loss of Postn does not affect
canonical Wnt signaling in ErbB2-driven tumors. Fur-
thermore, this suggests that the impaired tumor growth
observed in Postn(−/−) mice is unlikely due to deficient
Wnt signaling.Previous studies have shown that the lack of Postn
during embryonic development results in aortic valve
defects [50]. These anomalies are due to increased ex-
pression of the Notch1 antagonist Dlk1 and suppression
of Notch signaling. Similarly, Postn association with
Notch1 has been found to maintain Notch1 levels under
stress conditions [51]. As Notch also plays an important
role in mammary carcinoma and stem cell function
[52-55], we investigated whether Postn-deficient tumors
also displayed alterations in the Notch pathway. As Dlk1
mRNA levels were unaffected (not shown), we directly
assessed the levels of active Notch and its downstream
target Hey1 in mammary tumors derived from wild-type
and Postn-deficient animals.
Western blot analysis revealed a 3-fold decrease in the
levels of the transcriptionally active Notch intracellular
domain fragment (NICD; reviewed in [52]) (Figure 4A).
This was accompanied by an approximately 50% down-
regulation in Hey1 mRNA levels, a NICD target gene
(Figure 4B). However, Hes1 levels remained unchanged
Figure 3 Loss of Postn alters FAK signaling and delays tumor
growth at heterotopic sites. (A) Total cell lysates from 3
independent tumors were surveyed for FAK activation. Lower levels
of FAK activation (pFAK-Y397) were observed in Postn-null tumors.
(B) Western blot analysis for activated Akt (pAkt; S473) and Cyclin
D1 showed no differences in Postn(−/−) tumors when compared to
wild-type. (C) Tumor volume measurements following the
subcutaneous injection of 106 Met-1 cells into the flank of FVB/N
wildtype or Postn-null female mice (n=5). No appreciable growth
was observed in Postn-null mice suggesting that Postn is required
for tumor progression at heterotopic sites. *P <0.05 (D)
Representative tumors excised at 35 days following the injections
of Met-1 cells as described in (C).
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activation of Hes1 transcription is context and cell type-
dependent [56]. Together our results suggest that the
loss of Postn is accompanied by reduced Notch1 activity
and a failure to support tumor growth at secondary
sites.
Postn drives tumor growth by activating Notch1
Our data suggest that high Notch activity is required for
tumor growth at heterotopic sites. Therefore, we testedwhether increased Notch activity was sufficient to bypass
the Postn requirement in our heterotopic model. Met-1
cells stably expressing NICD were generated and com-
pared to Met-1 expressing Postn or a nuclear
localization signal mutant NICD construct (ΔNLS;
Figure S5 in Additional file 6). In cell culture, overex-
pression of Postn in Met-1 cells resulted in a γ-
secretase-dependent upregulation of NICD protein levels
(Figure 4C), suggesting that Postn signaling in mammary
tumor cells can contribute to the regulation of active
Notch levels. The upregulation of NICD in Postn-
expressing cells was accompanied by a 4-fold increase in
Hey1 mRNA levels (Figure 4D). Met-1 cells expressing
NICD upregulated Hey1 mRNA by more than 50-fold.
In contrast, no induction was observed in control cells
expressing the NLS mutant form of NICD. When
injected subcutaneously into Postn-deficient FVB/N
female mice, Met-1 cells expressing NICD grew as
well as in wild-type mice, suggesting that NICD re-
expression is sufficient to bypass the Postn requirement
observed for control cells (Figure 4E). Interestingly, in
wild-type mice, NICD overexpression did not enhance
tumor growth beyond what was observed for control
cells, suggesting that the levels of downstream NICD
effectors might be limiting. Expression of the inactive
NICD could not rescue the Met-1 growth defect in
Postn-null mice, suggesting that Notch activity is
required.
Interestingly, Postn or NICD expression in Met-1 cells
did not enhance the activity of a β-catenin reporter gene
(Figure S4 in Additional file 5), suggesting that Notch1
does not bypass the Postn requirement by indirectly
stimulating the Wnt system. Although Notch1 has been
previously shown to play a role in the expansion of pre-
malignant and tumor-initiating cells in NICD-induced
mammary tumors [55,57], we did not find any differ-
ences in the primary or secondary tumorsphere forming
ability of primary tumors derived from Postn-null mice
(Figure S6 in Additional file 7), suggesting that the loss
of Postn has no effect on the primary tumor stem cell
compartment.
To test the requirement for the Notch pathway in a
wild-type environment, a dominant-negative form of the
Notch co-activator Mastermind-like 1(dnMAML1; [58])
was overexpressed in Met-1 cells. Expression of
dnMAML1 in Met-1 cells resulted in Hey1 downregula-
tion and poor tumor growth upon subcutaneous injec-
tion (Figure 4F). Furthermore, expression of dnMAML1
resulted in a 50% decrease in tumor take rate when
compared to GFP-expressing control cells (GFP: 5/6 vs
dnMAML1: 8/16). Together, these data suggest that
Postn is necessary to maintain a threshold level of active
Notch, required for tumor establishment and growth at
heterotopic sites.
Figure 4 Active Notch expression can bypass the Postn requirement for heterotopic growth of Met-1 cells. (A) Western blot analysis of
tumor lysates showing a marked reduction of active Notch levels in Postn-null tumors. This is accompanied by a 2-fold reduction in the levels of
Hey1 gene expression as measured by Q-PCR (B; *P <0.01). The data shown are an average of 4 independent tumors performed in triplicate. (C)
Western blot analysis of Postn- or NICD-expressing Met-1 cells. Cells expressing Postn showed a marked increase in endogenous NICD levels
when compared to vector control (pLPCX). The increase in endogenous NICD was blocked by the addition of a γ-secretase inhibitor (GSI).
Overexpression of exogenous NICD was only detectable with a total Notch antibody as the anti-NICD epitope has been deleted in the construct.
Similarly, expression of the NLS mutant can only be detected by Q-PCR as it lacks both epitopes recognized by the commercial anti-NICD and
anti-Notch antibodies. (D) Quantitation of Hey1 mRNA levels showed a 4- and 70-fold increase in Met-1 cultures overexpressing Postn or NICD,
respectively (*P <0.01). No increase was observed in ΔNLS-expressing cells. (E) Tumor volume measurements at 28 days post-injection of Met-1
cells overexpressing NICD or ΔNLS in wildtype or Postn-null mice. Cells over-expressing NICD could bypass the Postn requirement for subcutaneous
growth in FVB/N females. Little or no growth was observed for ΔNLS-expressing cells (*P <0.01). (F) Expression of dnMAML1 in Met-1 cells impairs their
growth in wildtype mice when compared to a GFP-expressing control (*P <0.01).
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apocrine-like phenotype
Although loss of Postn did not affect overall survival and
tumor development, our results show that it impaired
tumor growth at heterotopic sites. In addition, careful
histological examination of these tumors revealed a mo-
lecular apocrine-like phenotype, characterized by abun-
dant granular eosinophilic cytoplasm, vesicular nuclei
with prominent nucleoli (Figure 5A,B). The molecular
apocrine phenotype is a characteristic of androgen
receptor (AR)-positive breast cancers [59,60]. Therefore,
we assessed AR protein levels in wild-type and Postn-
null NeuNDL tumors by Western blot analysis. Al-
though AR mRNA levels were unchanged (not shown),
AR protein levels were found to be upregulated 2-fold in
the majority of tumors derived from Postn-null mice
(Figure 5H). Furthermore, immunohistochemical ana-
lysis for AR expression revealed a significant increase in
nuclear localization of AR in tumors from Postn-null
animals, suggesting an increase in AR activity
(Figure 5C-G). The increase in AR protein levels in
Postn-null tumors suggests a posttranscriptional upregu-
lation or stabilization of AR protein levels [61,62]. Inter-
estingly, we have identified one tumor sample where AR
levels were unchanged which could be correlated with
wild-type levels of active and total Notch. Together these
findings demonstrate that the loss of Postn results inNotch downregulation which is accompanied by AR up-
regulation in the primary tumors. Furthermore, this sug-
gests that the loss of Postn in ErbB2-expressing tumors
confers an AR+ apocrine-like phenotype.
To gain further insights into the molecular mecha-
nisms regulating tumor progression in a Postn-null en-
vironment, we compared the gene expression profiles of
Postn(−/−) and Postn(+/+) tumors using Affymetrix mi-
croarrays. Table S2 in Additional file 1 shows the genes
that were up- or downregulated by at least 10-fold in
Postn-null tumors. Supporting the histological findings,
numerous genes that have been previously reported as
AR target genes, such as the androgen-binding proteins
[63] and PIP [64] were upregulated in Postn-null tu-
mors. These observations suggest that the activation of
critical genes in the absence of Postn allows primary
tumor growth in the absence of high Notch activity.
In human tumors, PIP (PIP/GCDFP15) expression was
shown to be associated with AR+ molecular apocrine-
like tumors [65-67]. To confirm the array data, Q-PCR
was performed on tumor RNA to validate PIP overex-
pression in Postn-null tumors. In addition, we assessed
the mRNA levels of androgen-binding proteins (Abp),
previously shown to be upregulated by testosterone in
cultured cells [63]. Quantitative PCR analysis revealed
that both PIP and Abp (ε and ζ) were significantly up-
regulated in Postn-deficient tumors (Figure 6). Whereas
Figure 5 Loss of Postn leads to increased AR levels and activity. (A) H&E staining of primary tumors derived from wildtype (A) and Postn-
null mic (B). Postn-deficient tumors displayed an apocrine-like morphology with granular eosinophilic cytoplasm and prominent nucleoli. (C-F)
Immunohistochemical analysis of independent tumors from Postn-null mice shows an increase in AR levels and nuclear localization (G). At least
1000 nuclei from 3 independent tumors were assessed for AR nuclear translocation. The average and S.E.M. is shown. *P <0.05. (H) Western blot
analysis of Postn-null tumors reveals that Notch downregulation results in AR upregulation. Note one tumor sample where low AR levels can be
correlated to high levels of Notch.
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and ζ were upregulated by more than 1,000-fold
(Figure 6B), suggesting transcriptional activation of AR
target genes in tumors derived from Postn-deficient
animals.
Interestingly, in addition to being an AR-regulated
gene [64], PIP/GCDFP-15 has been demonstrated to be
expressed in a large proportion of human breast cancers
and to enhance the growth and invasion of breast cancer
cell lines [68-71]. In addition, PIP was found to activate
AR activity, which in turn, upregulates PIP transcription
in feed-forward loop [70]. As PIP is an AR target gene
that is highly induced in tumors from Postn-null mice,
we tested the possibility that PIP expression in wild-type
Met-1 cells could compensate for the absence of Postn
in vivo. The murine PIP cDNA was cloned and stably
expressed in Met-1 cells and pools were injected sub-
cutaneously in Postn-null female mice. Similar to NICD-
expressing cells, at the 4-week end point, Met-1 cells
overexpressing PIP formed large tumors in Postn-null
mice that were comparable in size to those observed in
wild-type animals (Figure 6C). Control puromycin-
resistant cells grew very poorly in the Postn-deficient
environment. These results suggest that PIP is a major
downstream effector of AR activation and that its
expression in Met-1 cells is sufficient to overcome the
Postn deficiency in vivo. However, mechanistically, it is
likely that the rescue by NICD and PIP proceeds
through distinct pathways.Further, AR levels did not change in control and NICD
expressing subQ tumors in Postn-null mice as compared
to subQ tumors grown into wild-type mice (Figure S5B
in Additional file 6), suggesting that the NICD growth
rescue in null mice does not result in an apocrine
phenotype. Together, our results show that the loss of
Postn leads to Notch downregulation and selects for
AR-positive molecular apocrine-like tumors.
Discussion
HER2/ErbB2/Neu is overexpressed in about 30% of hu-
man breast cancers and is associated with poor progno-
sis (reviewed in [5]). As high levels of Postn have been
found to be associated with breast cancer progression
[19-21], we have derived Postn-deficient mice in the
MMTV-Neu background. Supporting previous findings
[22], our data show that the loss Postn does not impair
mammary gland development, suggesting that it can
proceed through Postn-independent mechanisms. In
addition, Postn deletion did not affect the onset or progres-
sion of mammary tumors in FVB/N mice. Surprisingly,
wild-type Met-1 cells grew very poorly in a Postn-deficient
environment. This growth defect was rescued by
re-expressing active Notch1, suggesting that Postn is
required to maintain Notch1 activity (see Figure 7). Sup-
porting this, expression of a dominant negative Notch
co-activator, MAML1, suppressed heterotopic tumor
growth in a wild-type environment, suggesting that the
Notch pathway plays a critical role in this process.
Figure 6 The AR target gene PIP rescues tumor growth in
Postn-null mice. Q-PCR expression analysis shows that the AR
target genes prolactin-induced protein (PIP; *P <0.05) (A) and
androgen-binding proteins ε and ζ (B) are markedly induced in
Postn-null tumors (*P <0.005). (C) Tumor volume measurements at
28 days post-injection of PIP- or Postn-expressing Met-1 cells.
Expression of PIP in Met1-cells rescues their subcutaneous growth
defect in FVB/N Postn-null females (*P <0.01). Postn-expressing
cells could not rescue the growth deficit in Postn(-/-) mice. Inset:
Ethidium bromide-stained PCR reaction showing expression of
exogenous PIP in Met-1 cells.
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levels in cardiac tissues from Postn-null mice, we did not
observe any changes in Dlk1 or Notch1 mRNA levels.
Postn has been demonstrated recently to interact with
Notch and to induce its processing under hypoxicFigure 7 Loss of periostin activates an AR response. Through an unkno
stimulates or maintains Notch processing and NICD activity (1). Loss of per
undefined mechanism (dotted lines). This is accompanied by Hey1 downre
development. Activation of the AR pathway or Notch signaling is sufficient
deficient environment tumor growth at heterotopic sites is impaired (3).conditions [51]. Deletion of Postn in periodontal ligaments
leads to a decrease in Notch processing and increased cell
death under stress conditions. One possibility is that in
the tumor microenvironment, a similar interaction is
required to maintain Notch activity.
Deletion of Postn in the MMTV-PyMT mouse model
also results in normal tumor initiation and progression
[22]. In addition, Postn-null tumor cells derived from
Py-MT-expressing mice are able to grow efficiently in
both wild-type and Postn-null mammary glands when
orthotopically transplanted in Rag2−/− mice [22]. This
supports the observations that primary tumors grow well
in both wild-type and Postn-null mammary gland envi-
ronments. This is in agreement with our findings show-
ing that Neu + primary tumors develop and progress
with similar kinetics in wild-type and Postn(−/−) mice.
Interestingly, orthotopic or tail vein injection of Postn
(−/−) Py-MT+ tumor cells results in very little lung
colonization [22]. As tumor cells themselves do not
express Postn, these data suggest that stroma-derived
Postn is required for efficient colonization of secondary
sites. Similarly, we find that subQ injection of wild-type
Py-MT+ cells results in very poor growth in Postn-null
mice, suggesting that Postn is required in the micro-
environment for efficient tumor growth at secondary
sites. Although a direct comparison between the differ-
ent models is difficult, our study and the data by
Malanchi et al. [22] support a role for Postn in the
establishment and growth of mammary tumors at
secondary sites.
As previously reported [22], we also did not find any dif-
ferences in the ability of Postn(−/−) primary tumor cells to
form tumorspheres or to modulate the canonical Wnt
pathway (see Figure S4 in Additional file 5). One possibil-
ity is that the requirement of Postn is critical only at
secondary sites for the expansion of cell subpopulations
through a Wnt-dependent system [22]. However, our datawn mechanism, the presence of Postn in the microenvironment
iostin (2) results in NICD downregulation and AR upregulation by an
gulation and the activation of AR target genes without any effect on
to drive normal mammary tumor progression. However, in a Postn-
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tion of an AR-dependent system is sufficient to bypass the
Postn requirement at secondary sites.
Interestingly, Postn has been shown to stimulate FAK
and Akt activation downstream of integrin receptors
under various conditions, contributing to increased inva-
sion, angiogenesis and survival [12,13,15-17]. Our ana-
lysis shows that tumors derived from Postn-null animals
display reduced levels of active FAK, supporting a role
for Postn in their activation in vivo. However, no
changes in phospho-Akt were observed, suggesting that
additional pathways can maintain Akt activity. This is in
marked contrast to what has been reported for pancre-
atic cancer cells [16]. Interestingly, overexpression of
Postn in 293 cells has been reported to increase angio-
genesis through FAK activation and vascular endothelial
growth factor (VEGF) production [20]. However, no dif-
ferences were observed in the number and size of CD31-
positive blood vessels in tumors derived from Postn-null
animals, suggesting that in this model, tumor angiogen-
esis can proceed without Postn.
Our data show that the loss of Postn results in
reduced Notch activity and Hey1 transcription. Previous
studies have shown that Hey1 and Hey1L can modulate
AR transcriptional activity [72,73]. Similarly, expression
of active Notch was found to downregulate AR activity
in prostate cancer cells. Supporting these observations,
we find that an approximate 50% decrease in Hey1 levels
are accompanied with an increase in AR activity and tar-
get gene transcription. Interestingly, a 2-fold increase in
AR protein levels was also observed. Whether this is also
a Notch-regulated process in breast cancer cells remains
to be investigated.
In mammary tumors from Postn-null mice, we have
observed an increase in AR levels and an upregulation of
its target genes PIP and Abp. The role of AR in
hormone-dependent cancers is well documented [24].
However, the AR has recently received much attention
as a novel therapeutic target in breast cancer [24-26]
and a role for AR activation in a proportion of HER2+
cancers has been reported [26,28-30]. Recently, a large
proportion of AR-positive molecular apocrine breast
cancers have been shown to overexpress HER2 or PIP,
an AR target gene [74]. Although PIP-null mice show no
overt phenotype [75], PIP has been shown to be highly
expressed in Luminal A and HER2 subtypes [71]. Silen-
cing of PIP in T47D cells lead to a repression of MYC
and decreased proliferation. In addition, decreased FAK,
ERK and Akt activation were also observed. This sup-
ports other data that demonstrated a role for PIP in cell
invasion [69]. Furthermore, a feed-forward loop between
AR and PIP has been established [70]. These studies
showed that PIP can induce AR expression and activity
by stimulating its nuclear translocation. Similarly, wefind that loss of Postn stimulates AR activity and target
gene expression in primary tumors. Whether the estab-
lishment of a feed-forward loop in mammary tumors
also follows the initial AR activation remains to be inves-
tigated. Nevertheless, our results show that deletion of
Postn and upregulation of PIP is sufficient to overcome
the loss of Postn in vivo, suggesting that PIP is a major
effector of the AR response. How PIP mediates its
effects on growth and invasion remains to be uncovered.
Conclusions
Overall, our results show that Postn is not required for
mammary gland development and ErbB2-driven tumori-
genesis. However, deletion of Postn results in decreased
Notch activity and an upregulation of AR levels that
confers an apocrine-like subtype (Figure 7). We find that
the growth defect of mammary tumor cells at hetero-
topic sites in a Postn-deficient environment can be
rescued by NICD or PIP expression.
Additional files
Additional file 1: Table S1. Primer pairs used in this study. Table S2.
Microarray data showing the relative levels of genes for which the
expression was altered by at least 10-fold in Postn-null tumors. Results
are the average fold change from two independent tumors for both
wild-type and Postn(−/−).
Additional file 2: Figure S1. Postn deletion does not impair mammary
gland development. (A) Example of a genotyping run showing an
absence of the wild-type allele in homozygote mutant mice. (B) Western
blot analysis of whole mammary gland lysates showing Postn expression
in wild-type and heterozygotes. Postn reactivity is lost in Postn(−/−)
glands. Postn runs as 80-90 kDa glycosylated isoforms. Representative
images of mammary gland whole mounts from nulliparous (C-E) and
pregnant (F-H) FVB Postn+/+, Postn+/−, and Postn−/− mice at 8 weeks and
14.5 days post coitum (dpc). No differences were observed in ductal
outgrowth and arborization. (I-K) High magnification of panels shown in
F to H. Anti-Postn immunohistochemistry showing Postn expression in
wild-type mice (L and N). No reactivity was observed in Postn-null
mammary glands (M and O). Postn reactivity was found exclusively in the
stromal compartment lining the ducts (arrowhead). Some staining was
also observed in the adipose tissue.
Additional file 3: Figure S2. Deletion of Postn does not impair tumor
initiation. Representative H&E staining of a paraffin-embedded whole
mammary gland from Postn wild-type (A) or Postn(−/−) (B) females
showing multiple hyperplastic foci at 4 months of age. (C and D)
Magnification of the boxed area from A or B. (C) Quantitation of the
average number of hyperplastic lesions per section of whole mammary
gland in 4-month-old females.
Additional file 4: Figure S3. Postn deletion does not impair tumor
growth or angiogenesis. Frozen sections from wild-type mammary
tumors were immunostained for CD31 (A) or Ki-67 (C) to detect newly
formed blood vessels and proliferating cells, respectively. No differences
were observed when compared to Postn(−/−) tumors (B and D). (E)
Quantitation of Ki-67+ cells in three independent tumors. The proportion
of Ki-67+ cells was calculated relative to the total number of nuclei in the
field. At least 1,000 nuclei were counted.
Additional file 5: Figure S4. Postn deletion does not impair β-catenin
levels or signaling in tumor cells. (A) Western blot analysis showing total
β-catenin levels from three independent tumors from each genotype.
Representative of an anti-β-catenin IHC on a wild-type (B) or Postn-null
tumor (C) showing cytosolic and nuclear localization. No differences were
Sriram et al. Breast Cancer Research  (2015) 17:7 Page 12 of 14observed between the two genotypes. (D) TOP-Flash Luciferase assays on
Met-1 cells expressing Postn or active Notch (NICD). No further activation
was observed in the presence of Postn or NICD when compared to
vector control (pPLCX).
Additional file 6: Figure S5. (A) Q-PCR expression analysis of Notch
mRNA in NICD- and ΔNLS- transfected cultures. Exogenous NICD and
ΔNLS were found to be overexpressed 18- and 4-fold, respectively. (B)
Western blot analysis of AR protein levels in subQ tumors from various
Met-1 pools injected into wild-type or Postn-null mice.
Additional file 7: Figure S6. Loss of Postn does not affect tumorsphere
formation. Representative photomicrograph of tumorsphere cultures
derived from wild-type (A) and Postn-null (B) tumors. (C) Quantitation of
primary and secondary tumorspheres from both genotypes after 7 days
in cultures. No differences were observed in the number and size of the
spheres between wild-type and Postn-null tumors. Spheres were counted
from five independent tumors and tumorsphere cultures could be
established from all tumor samples.
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